Sarcoplasmic reticular and myofibrillar activities in PO-induced cardiac dysfunction in rats with or without CAP and LOS treatments for 8 weeks
| Parameters | Control | PO | PO + CAP | PO + LOS |
|---|---|---|---|---|
| A. Cardiac function | ||||
| LVDP (mmHg) | 122 ± 2.8 | 90 ± 3.1 | 114 ± 2.5 | 112 ± 2.5 |
| LVEDP (mmHg) | 3.6 ± 1.0 | 10.8 ± 2.1 | 4.5 ± 0.6 | 5.7 ± 0.4 |
| B. SR activity and protein and gene expression | ||||
| Ca2+-uptake (nmol Ca2+/mg per min) | 80.0 ± 3.6 | 46.7 ± 1.8 | 70.7 ± 1.8 | 67.0 ± 3.7 |
| Ca2+-release (nmol Ca2+/mg per min) | 20.5 ± 1.9 | 13.0 ± 0.9 | 18.2 ± 0.9 | 17.2 ± 0.9 |
| Ca2+-stimulated ATPase protein content (% of control) | 100 | 80.0 ± 0.4 | 94.0 ± 2.0 | 92.06 ± 3.0 |
| Ca2+-stimulated ATPase mRNA levels (% of control) | 100 | 56.0 ± 2.0 | 88.0 ± 3.0 | 86.0 ± 3.0 |
| C. MF and myosin activities | ||||
| MF Ca2+-stimulated ATPase (μmol Pi/mg per h) | 11.5 ± 0.8 | 5.9 ± 0.02 | 10.1 ± 0.88 | 9. 81 ± 0.22 |
| Myosin Ca2+-ATPase (μmol Pi/mg per h) Myosin mRNA levels (Relative intensity) | 18.8 ± 0.5 | 12.7 ± 0.02 | 17.4 ± 0.5 | 16.9 ± 0.5 |
| α-MHC | 0.28 ± 0.02 | 0.13 ± 0.03 | 0.23 ± 0.02 | 0.22 ± 0.01 |
| β-MHC | 0.03 ± 0.01 | 1.18 ± 0.10 | 0.08 ± 0.01 | 0.10 ± 0.02 |
Values are mean ± SE of 6 animals in each group. CAP: captopril (2 g/L); PO: pressure overload; LVDP: left ventricular developed pressure. Data are based on the analysis of the information in Figures 1, 3, 4, 5 and 6 in our paper Liu et al. Clin Exp Hypertens. 1999;21:145–56 [153]. *P < 0.05 compared with control; †P < 0.05 compared with PO group